The National Health Council Supports Generic Drugs as a Way to Reduce Health Care Costs WASHINGTON, DC (April 27, 2017) – The Association for Accessible
Background – What are REMS and What is Current Law? Under the Food and Drug Administration Amendments Act (FDAAA) of 2007, FDA can require manufacturers
Governor Hogan Should Veto Legislation To Keep Generic Drugs Affordable for Maryland WASHINGTON, DC (April 10, 2017) Generic drugs have been and continue to be
Health Care Groups Also Back New Bill to Ensure Access at Lower Costs WASHINGTON, DC (April 7, 2017) – The Association for Accessible Medicines (AAM)
April 6, 2017 The Honorable David McKinley The Honorable Peter Welch Dear Congressmen McKinley and Welch: As stakeholders firmly committed to fostering patient access to
On March 15th, The Atlantic presented “The Next Drugs: The Future for Biosimilars – An Atlantic Policy Briefing” at the Newseum in Washington, D.C. Underwritten by the Biosimilars Council, more than 100
Statement of Chester “Chip” Davis Jr., President and CEO of the Association for Accessible Medicines on the Confirmation of Seema Verma as Administrator of the
Statement of Chester “Chip” Davis Jr., President and CEO of the Association for Accessible Medicines on the Nomination of Dr. Scott Gottlieb as Commissioner of
What does the future hold for biosimilars? How will the new administration, changing regulations and the recent FDA draft naming guidelines impact the industry? On
Generic Pharmaceutical Association Becomes Association for Accessible Medicines Education Campaign Reinforces Generics Reduce Drug Costs, Drive Savings (Feb. 14, 2017) — The Generic Pharmaceutical Association,
WASHINGTON, DC (February 10, 2017) – “We congratulate Secretary Price on today’s confirmation and look forward to working with his team, President Trump and both
Download now From Chip Davis, President & CEO 2016 marked the 15th anniversary of the founding of the Generic Pharmaceutical Association. Our achievements over the
